AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Published: 16 November 2023
14m 32sPart 1 | Session 6 AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health
10m 36sPart 1 | Session 7 AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF
9m 14sPart 1 | Session 8 An Extended Duration Short-Interfering RNA Targeting Lp(a)
11m 15sPart 1 | Session 9 ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin
15m 26sPart 1 | Session 10 ARIES HM3: Avoidance of Aspirin with LVAD Devices
14m 58sPart 1 | Session 1 ORBITA-2: PCI for Stable Angina Rasha Al-Lamee, Nazli Okumus, Christopher Rajkumar
11m 47sPart 1 | Session 2 SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients A Michael Lincoff , Ahmed Ghoneem
16m 5sPart 1 | Session 3 MINT: Myocardial Ischaemia & Transfusion Nazli Okumus, Jeffrey L Carson
11m 41sPart 1 | Session 4 KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension George L Bakris, Sukriti Banthiya
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.
These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
More from this programme
Radcliffe & Cardionerds @AHA23
About the episode
AHA 23 — Dr Hanad Bashir, CardioNerds ambassador, interviews Prof William T Abraham (The Ohio State University, US) on the findings of a clinical evaluation of the Cordio app in adult patients with acute decompensated heart failure.
The Cordio "HearO" app (Cordio Medical) uses patient speech sampled via mobile phone to sense fluid accumulation related to chronic heart failure, and provides alerts prior to hospitalisation. This observational study enrolled 89 patients, who used the HearO app at hospital admission and release.
Findings shows that The sensitivity detection rate of HearO speech analysis-based telemonitoring was superior to that of daily weight monitoring.
Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.
Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
Dr. Hanad Bashir is a second year general cardiology fellow at The Christ Hospital in Cincinnati, Ohio. He is originally from Toronto, Canada, and received his medical training in Wuhan, China. He completed his internal medicine training at Cleveland Clinic Akron General in Akron, Ohio. He enjoys learning about all topics in cardiology. However, he has a particular interest in interventional and critical care cardiology.
William T Abraham
Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine
Prof Abraham is a College of Medicine Distinguished Professor. He has been recognized as one of the “Best Doctors in America” for 18 consecutive years.
His research has led to the approval/adoption of new heart failure therapies, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic monitoring, transvenous phrenic nerve stimulation, cardiac contractility modulation, baroreflex activation therapy, and mitral valve repair.
Prof Abraham has authored more than 1,000 original works and has been named a Clarivate Analytics Highly Cited Researcher and one of The World’s Most Influential Scientific Minds.
He received the 2017 Distinguished Scientist Award from the American College of Cardiology.
With his permission, Prof Abraham is contactable here.